Sarcoidosis is a systemic disease of unknown etiology defined by the presence of
noncaseating granulomatous inflammation that can cause organ damage and diminished …

Despite the large number of performed studies, the etiology and pathogenesis of sarcoidosis
still remain unknown. Most researchers allude to the possible autoimmune or immune …

Objective: To describe clinical and imaging responses in neurosarcoidosis to infliximab, a
monoclonal antibody against tumor necrosis factor–α. Methods: Investigators at 6 US …

Objective To compare longitudinally extensive myelitis in neuromyelitis optica spectrum
disorders (NMOSD) and spinal cord sarcoidosis (SCS). Methods We identified adult patients …

Sarcoidosis is a multi-system disease of unknown etiology characterized by granuloma
formation in various organs (especially lung and mediastinohilar lymph nodes). In more than …

Sarcoidosis is a systemic granulomatous disease that develops due to the Th1, Th17 and
Treg lymphocytes disturbance. There is an assumption, that B cells and follicular T-helper …

Sarcoidosis is a chronic disease characterised by granulomatous depositions that can occur
in virtually any organ system [ 1]. Currently, there is no US Food and Drug Administration …

Sarcoidosis is a systemic disorder characterized by the aberrant development of
granulomas within various organs in the body. The lungs are involved in 90% of patients …

In general, sarcoidosis treatment should be offered to palliate symptoms and improve quality
of life or to prevent end-organ disease. Symptoms include pulmonary as well as extra …

The treatment options for pulmonary sarcoidosis have increased over the past 10 years. As
new treatments have been introduced, the best way to assess and compare treatments …